L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

Nicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, Johanna Breuer, Kerstin Goebel, Susanne Windhagen, Bruno Brochet, Patrick Vermersch, Christine Lebrun-Frenay, Anita Posevitz-Fejfar, Ruggero Capra, Luisa Imberti, Vera Straeten, Juergen Haas, Brigitte Wildemann, Joachim Havla, Tania Kuempfel, Ingrid Meinl, Kyle Niessen, Susan GoelzChristoph Kleinschnitz, Clemens Warnke, Dorothea Buck, Ralf Gold, Bernd C. Kieseier, Sven G. Meuth, John Foley, Andrew Chan, David Brassat, Heinz Wiendl

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)865-871
JournalNeurology
Volume81
Issue number10
DOIs
Publication statusPublished - 3 Sep 2013

Cite this

Schwab, N., Schneider-Hohendorf, T., Posevitz, V., Breuer, J., Goebel, K., Windhagen, S., Brochet, B., Vermersch, P., Lebrun-Frenay, C., Posevitz-Fejfar, A., Capra, R., Imberti, L., Straeten, V., Haas, J., Wildemann, B., Havla, J., Kuempfel, T., Meinl, I., Niessen, K., ... Wiendl, H. (2013). L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 81(10), 865-871. https://doi.org/10.1212/WNL.0b013e3182a351fb